Glaucoma is the leading cause of irreversible blindness worldwide. It is also one of the quietest diseases in ophthalmology: the early stages are typically symptom-free, and by the time most people notice anything is wrong, a measurable fraction of the retinal ganglion cells in the affected eye are already gone. The standard early-detection tools — intraocular pressure measurement, optical coherence tomography of the optic nerve head, and automated visual field testing — catch many cases before they reach that point, but they don't catch all of them equally early.
There is a second functional measurement, less often used in routine screening, that can register optic-nerve dysfunction in some patients before a visual field defect is recordable on perimetry: contrast sensitivity. It isn't a substitute for an ophthalmologic exam, and it isn't specific enough to diagnose anything on its own. But it is a low-cost, repeatable signal you can collect on your own setup and bring to an eye doctor. The rest of this post is about why that signal exists in glaucoma, what the literature shows, and what an at-home CS test can and cannot tell you about glaucoma risk.
If you are over 40, have a family history of glaucoma, or are in one of the recognised higher-risk groups: please see an ophthalmologist for a comprehensive eye exam. A contrast-sensitivity test is a useful adjunct, not a replacement.
What glaucoma does to vision
Glaucoma is, fundamentally, a disease of the retinal ganglion cells (RGCs) — the output neurons of the retina, whose axons converge at the optic nerve head and project to the brain. In glaucomatous optic neuropathy, these cells die, usually progressively, often (though not always) in association with elevated intraocular pressure. Each lost ganglion cell is a small piece of visual information that no longer reaches the brain.
A piece of anatomy matters for understanding why contrast sensitivity sometimes registers this loss early. Retinal ganglion cells come in physiologically distinct classes, the two largest being the magnocellular (M) and parvocellular (P) cells. Magnocellular cells have larger receptive fields, faster temporal responses, and are tuned to lower spatial frequencies, motion, and broad luminance change; parvocellular cells are tuned to fine detail and colour. A long line of post-mortem and primate work — including the Quigley laboratory's papers on glaucomatous optic nerves — has documented that in early glaucoma, larger-diameter axons (which include the magnocellular projection) appear to be preferentially affected, while smaller-diameter axons are relatively spared until later stages (Quigley, Dunkelberger & Green, 1989).
That selective vulnerability has a measurable functional signature. Because magnocellular cells contribute disproportionately to detection of low-to-mid spatial-frequency patterns, early magnocellular loss tends to show up as reductions in the low-to-mid frequency portion of the contrast sensitivity function — the band around 1 to 6 cycles per degree of visual angle that covers faces, edges, and broad scene structure.
The clinical importance is in the timing. The gold standard for detecting glaucomatous functional loss is standard automated perimetry — the white-on-white visual field test most patients have seen. Perimetry is excellent once damage is present, but a meaningful fraction of retinal ganglion cells can be lost before a reliable visual field defect emerges. Histopathological studies have estimated that something on the order of 25 to 40 percent of retinal ganglion cells in a given retinal region can be missing before the corresponding field defect becomes reliably detectable (Kerrigan-Baumrind, Quigley, Pease, Kerrigan & Mitra, 2000). By the time the defect is there, the loss is irreversible — surviving cells can be protected, but lost ones cannot be brought back.
The case for contrast sensitivity as a complementary measurement is that it may register functional change while ganglion cell loss is too small or too diffuse to produce a reliable perimetric defect, and well before any change in standard visual acuity.
What the literature shows
Contrast sensitivity in glaucoma has been studied for decades. A few honest summaries of what that body of work supports — and what it does not.
Contrast sensitivity is reduced in early and moderate glaucoma, on average. Multiple studies using clinical instruments — the Pelli-Robson chart, the FACT/Vistech grating chart, the CSV-1000 — have found that groups of glaucoma patients perform worse than age-matched controls, including subgroups whose visual fields were within normal limits or only borderline abnormal. The pattern across spatial frequencies is most often a broad reduction emphasising the lower-to-mid range, consistent with the magnocellular-vulnerability picture above. The reductions are robust at the group level; magnitudes are modest in early disease and grow with worse perimetric stage.
The relationship to disease stage is variable, and the test is not perfectly sensitive. Group averages hide within-group variability. Not every patient with early glaucoma shows reduced contrast sensitivity, and some patients with reduced contrast sensitivity have no glaucoma. Glaucoma is heterogeneous, and the instruments themselves have ceiling effects, test-retest variability, and sensitivity to incidental factors like refraction, lighting, and fatigue.
Tests that probe the magnocellular pathway tend to be more sensitive to early glaucoma. This is the logic behind frequency-doubling technology (FDT) perimetry, which exploits a low-spatial-frequency flickering stimulus processed predominantly by a magnocellular sub-population, and short-wavelength automated perimetry (SWAP), which targets the blue-yellow pathway. Sample, Taylor, Martinez and colleagues established that pathway-selective perimetric strategies can predict subsequent standard-perimetry defects in glaucoma suspects (Sample, Taylor, Martinez, Lusky & Weinreb, 1993). The general lesson — that targeting subsets of the visual system other than the white-on-white pathway can pick up early functional change — supports the idea that mid-spatial-frequency contrast sensitivity is worth measuring.
Methodology matters. The Pelli-Robson chart is a letter-based test at one effective spatial frequency, well-validated, with published normative values stratified by age (Mäntyjärvi & Laitinen, 2001). The FACT/Vistech chart samples five spatial frequencies but suffers from ceiling effects and coarse contrast quantisation. Adaptive grating procedures like the quick contrast sensitivity function (qCSF) method (Lesmes, Lu, Baek & Albright, 2010) can estimate a full curve in a few minutes with substantially better psychometric properties. A reduction on one instrument cannot be directly compared with a normal result on another.
Two honest caveats. First, no contrast sensitivity test — clinical or online — has been validated as a stand-alone screening test for glaucoma against a clinical-diagnosis reference standard in an unselected population. The work supports it as a correlate and complement, not a stand-alone instrument. Second, an online consumer-screen implementation is necessarily noisier than a calibrated clinical instrument. The underlying signal is the same; the measurement environment is not.
What an online CSF test can tell you about glaucoma risk
The honest framing: a screening signal, not a diagnosis. A reduction does not mean you have glaucoma. A normal result does not mean you don't. It is one input among several.
What it can usefully do is flag that the part of vision that glaucoma sometimes affects appears to be performing below typical for your age — worth bringing into a conversation with an eye doctor, especially if you are in a higher-risk group. The recognised risk groups include:
- Age over 40, with prevalence climbing further past 60.
- Family history of glaucoma — first-degree relatives carry roughly two to four times the population risk.
- Black or Hispanic/Latino ancestry, with substantially higher prevalence and earlier onset of primary open-angle glaucoma in population studies.
- High myopia — moderate-to-high myopic patients have higher rates of glaucomatous optic neuropathy.
- Prior eye trauma, which can produce a delayed-onset angle-recession glaucoma years later.
- Long-term ocular or systemic corticosteroid use, which can elevate intraocular pressure in steroid responders.
If one or more applies, a below-typical contrast sensitivity result is worth more attention than if none do.
Take the result to an ophthalmologist. The proper workup, broadly:
- A comprehensive eye examination, including refraction and ocular history.
- Intraocular pressure (IOP) measurement by Goldmann applanation tonometry. IOP is a major risk factor — but patients with normal-tension glaucoma have IOP in the statistically normal range.
- A dilated fundus examination with attention to the optic nerve head — cup-to-disc ratio, asymmetry between eyes, disc haemorrhages, peripapillary atrophy.
- Optical coherence tomography (OCT) of the optic nerve head and the retinal nerve fibre layer, which can quantify structural thinning before clinical signs are obvious.
- Standard automated perimetry, and increasingly ganglion cell complex measurements on SD-OCT.
- Gonioscopy to rule out narrow-angle or angle-closure mechanisms.
Each measurement is partial; the combination is what produces a diagnosis. A contrast sensitivity result is not part of that bundle today, but it can sit alongside it as functional context — particularly when it draws attention to a problem that might otherwise have gone unnoticed.
What it cannot tell you
Note. A contrast sensitivity test is a screening signal of overall visual function. It does not diagnose glaucoma — or any other condition — and it cannot replace an ophthalmologic exam.
A normal contrast sensitivity result does not rule out glaucoma. Early disease, particularly in patients whose magnocellular pathway happens not to be the first affected, can present with normal CSF on a screening test. Many patients with structurally documented optic nerve change still test within typical limits on contrast sensitivity. A clean result is reassuring, not exonerating.
A reduced contrast sensitivity result does not mean you have glaucoma. The list of other things that lower CS is long: refractive error (the most common cause by a wide margin — make sure your prescription is current), cataract, dry eye, diabetic retinopathy, MS, post-concussion vision change, normal aging, fatigue, medications, low room lighting, and test-setup issues. Many of these are more common than glaucoma.
An online CSF test cannot reliably distinguish asymmetry between the eyes, which is one of the clinical features that prompts glaucoma suspicion. Glaucoma is often unilateral or asymmetric in its early stages. Our v0 binocular test does not separate eye-by-eye performance. If asymmetry is on the table, this is a test that gets done in a clinic, with one eye occluded and a calibrated instrument.
A single result is a snapshot, not a trend. Test-retest variability is real; a single below-typical result is sometimes a setup issue, a tired afternoon, or a calibration drift. A pattern across multiple sessions on the same device is more meaningful than any one number.
Contrast sensitivity is a real functional measurement, and there is real reason to believe it carries an early-glaucoma signal. It is also noisy, and its specificity for glaucoma is poor enough that it cannot stand alone. "Useful signal" plus "low specificity" is what defines a screening signal — informative as one input, harmful if treated as a conclusion.
Practical next steps
What to do, depending on where you land:
If you are in a higher-risk group: see an ophthalmologist for a comprehensive exam. The recommended interval for screening eye exams over 40 is generally one to two years, more frequent with additional risk factors. Take a CS result if you have one, but the eye exam is what matters. Don't wait for an at-home test result to prompt the appointment.
If you are not in a higher-risk group and your CS is normal: the result is consistent with a healthy visual system on this axis. It does not replace a routine eye exam, which checks for refractive change, ocular surface health, retinal disease, and many things the CSF doesn't reach.
If your CS is below typical: don't panic. Many causes, most more common than glaucoma. Make sure your refraction is current; retest after a good night's sleep on the same device in similar lighting; check that your screen and room are set up well (mid-brightness, no glare). If the result is consistent across two or three sessions, bring it to an eye exam. Ask specifically about the optic nerve head and the retinal nerve fibre layer if glaucoma is in your family.
The longer background on what contrast sensitivity is and why it matters lives in the primer post; the calibration and adaptive-procedure details for the test we built live on the methodology page.
Take the test
Take the test now. Save the result. If you are in a higher-risk group, bring it to your next eye appointment — and please don't substitute a screening number for the appointment itself.
Glaucoma is a slow, quiet disease. Patients do best when it is caught early, and "early" by perimetric standards is sometimes later than anyone would like. A contrast sensitivity result is one extra thread of evidence the clinic visit can be built around. The thread is not the rope.
References
- Quigley, H. A., Dunkelberger, G. R., & Green, W. R. (1989). Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. American Journal of Ophthalmology, 107(5), 453–464. Histopathological study of retinal ganglion cell counts and perimetric findings in glaucomatous eyes, part of the line of work supporting selective large-fibre vulnerability in early glaucoma.
- Kerrigan-Baumrind, L. A., Quigley, H. A., Pease, M. E., Kerrigan, D. F., & Mitra, R. S. (2000). Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Investigative Ophthalmology & Visual Science, 41(3), 741–748. Source for the estimate that a meaningful fraction of retinal ganglion cells can be lost before a corresponding visual field defect becomes reliably detectable on standard automated perimetry.
- Sample, P. A., Taylor, J. D., Martinez, G. A., Lusky, M., & Weinreb, R. N. (1993). Short-wavelength color visual fields in glaucoma suspects at risk. American Journal of Ophthalmology, 115(2), 225–233. Early paper from the UCSD glaucoma group establishing that pathway-selective perimetric strategies can detect functional change in glaucoma suspects before standard achromatic perimetry.
- Pelli, D. G., Robson, J. G., & Wilkins, A. J. (1988). The design of a new letter chart for measuring contrast sensitivity. Clinical Vision Sciences, 2, 187–199. The Pelli-Robson chart paper — methodology anchor for clinical contrast sensitivity measurement.
- Mäntyjärvi, M., & Laitinen, T. (2001). Normal values for the Pelli-Robson contrast sensitivity test. Journal of Cataract and Refractive Surgery, 27(2), 261–266. Source of age-stratified normative Pelli-Robson values used as reference in clinical practice.
- Lesmes, L. A., Lu, Z.-L., Baek, J., & Albright, T. D. (2010). Bayesian adaptive estimation of the contrast sensitivity function: the quick CSF method. Journal of Vision, 10(3):17. The qCSF method underlying modern adaptive contrast-sensitivity testing.